Recently, the U.S. magazine Pharm Exec released its 2026 Pharm Exec Top 50 Companies, with Sino Biopharmaceutical Limited (SBP Group, 1177.HK) making the list for the 8th consecutive year.

Sino Biopharmaceutical Limited (SBP Group) takes the lead again in the "macromolecule patch" field! CPX301, the world's first weight loss dissolvable microneedle patch to receive clearance for a clinical trial from the U.S. Food and Drug Administration (FDA), has entered the clinical development stage.

On August 19, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced its 2026 interim results: In the first half of the year, it achieved revenue of RMB 19.44 billion, continuing the double-digit growth trend and reaching a new record high; the adjusted net profit attributable to the parent company from core business reached RMB 3.34 billion, a year-on-year increase of 92.3%, with revenue from innovative medicines and out-licensing becoming the core driver of performance growth. Meanwhile, the Company officially announced the launch of its global brand "SBP Group", articulating its strategy of "Science is where the company starts, Breakthroughs are what it pursues, and Patients are why it does what it does."

HONG KONG, Aug. 19, 2026 -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, today announced the launch of its new global brand, SBP Group, during its interim results meeting.

From August 11 to 16, the 2026 Health Industry Ecology Conference (HIE) was held in Boao, Hainan. Sino Biopharmaceutical Limited (SBP Group, 1177.HK) and its member companies Chia Tai Tianqing and CT Qingjiang won six major industry awards: SBP Group was simultaneously selected for the "Top 100 List of Comprehensive Competitiveness of China's Pharmaceutical Industry 2026" and the "Top 10 R&D Performers in China's Pharmaceutical Industry 2026", while Debaian/Zepolas, Tianqing Sule, Jiuli, and Saitanxin were listed on the "2026 Healthy China·Brand List" and "2026 Healthy China·New Drug of the Year".

Recently, Budesonide Suspension for Inhalation (Tianqing Suchang®), from SBP Group's (1177.HK) core enterprise Chia Tai Tianqing, received a GMP certificate and related marketing authorization from the Eurasian Economic Union (EAEU).

On August 6, the 12th indication for Anlotinib Hydrochloride Capsules (Fukewei®), independently developed by SBP Group's (1177.HK) core enterprise Chia Tai Tianqing, was approved for marketing.

On August 6, the second-generation Flurbiprofen Patches (Zepolas®) from Beijing Tide Pharmaceutical, a core enterprise of SBP Group (1177.HK), received a drug registration certificate from the National Medical Products Administration (NMPA) and was granted a 4-year data protection period.